Leukocyte Adhesion Deficiency Management Global Market Report 2024

The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $7.48 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The observed growth in the historic period for the management of leukocyte adhesion deficiency can be attributed to several factors. These include an increase in awareness and education about the disorder, advancements in genetic testing technologies, the designation of orphan drugs for specialized treatment, global health policies supporting rare diseases, the influence of patient advocacy groups, and advancements in pediatric healthcare. These factors collectively contributed to the progress made in addressing leukocyte adhesion deficiency during the historic period.

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the forecast period for the management of leukocyte adhesion deficiency can be attributed to the adoption of precision medicine approaches, the emergence of novel therapeutics, increased accessibility to genetic testing, a shift towards patient-centric drug development, and advancements in immunomodulatory therapies. Major trends expected in the forecast period include innovations in stem cell transplantation techniques, the integration of supportive therapies, the use of telemedicine for remote consultations, collaboration within research networks, and the incorporation of biomarker technologies to enhance diagnostic and treatment strategies.

The rising incidence of primary immunodeficiency (PID) is anticipated to drive the expansion of the leukocyte adhesion deficiency management market. PID encompasses a range of inherited disorders that compromise the immune system's functionality, rendering individuals more vulnerable to infections and diseases due to deficiencies in their immune responses. Managing leukocyte adhesion deficiency can significantly benefit those with primary immunodeficiency, potentially enhancing the understanding of immune system disorders and fostering the development of improved diagnostic techniques and therapies for these conditions. For example, statistics gathered during World Primary Immunodeficiency (WPI) Awareness Week 2023 by the Peace Hospital indicated that an estimated 60 lakh individuals worldwide are affected by PI, with 70% to 90% of cases remaining undiagnosed. Hence, the rising prevalence of primary immunodeficiency is set to propel the growth of the leukocyte adhesion deficiency management market.

The increasing prevalence of spinal cord injuries is expected to drive the growth of the leukocyte adhesion deficiency management market. Spinal cord injury, resulting from damage to any part of the spinal cord or associated nerves, often leads to complications such as autonomic dysfunction, including conditions such as hyperhidrosis. This issue is linked to heightened sympathetic activity in the spinal cord segment located just below the injury site. As indicated by the National Spinal Cord Injury Statistical Center (NSCISC) in March 2022, the estimated annual incidence of traumatic spinal cord injury (SCI) in the United States stands at approximately 54 cases per one million people, equating to about 18,000 new SCI cases annually. Moreover, the estimated count of individuals living with SCI in the United States ranges between 253,000 to 378,000, totaling around 299,000. Hence, the increasing prevalence of spinal cord injuries contributes to the growth of the leukocyte adhesion deficiency management market.

The expansion of the leukocyte adhesion deficiency management market is anticipated to be limited by the high cost of treatment. Leukocyte Adhesion Deficiency (LAD) is a rare condition characterized by issues in leukocyte adhesion and migration due to mutations in the ITGB2 gene. The treatment options for LAD are constrained, and the associated expenses can be substantial. These high treatment costs may restrict access to necessary therapies, hinder the adoption of new treatment approaches, and pose challenges in obtaining specialist consultations. For example, estimates from DVC Stem, a UK-based stem cell treatment clinic, indicate that expenses for a stem cell transplant, a treatment for leukocyte adhesion deficiency, can range widely from $15,000 to $75,000, potentially causing financial strain on patients. Hence, the exorbitant treatment costs are expected to limit the growth potential of the leukocyte adhesion deficiency management market.

Key players in the leukocyte adhesion deficiency management market are strategically concentrating on innovating novel therapies such as RP-L201 to address the fundamental genetic defects and enhance the quality of life for affected individuals. RP-L201, recognized as a Regenerative Medicine Advanced Therapy (RMAT), is designed to facilitate advanced gene therapy for treating leukocyte adhesion deficiency-I (LAD-I). For instance, Rocket Pharmaceuticals, Inc., a US-based clinical-stage company, secured U.S. Food and Drug Administration (FDA) designation for RP-L201 as an RMAT in March 2021. This designation was granted based on promising early-stage safety and efficacy data derived from the ongoing Phase 1/2 clinical trial of RP-L201. The RMAT designation is specifically intended to expedite the development and approval processes for regenerative medicine products, including cell and gene therapies. It is designated to products that demonstrate potential in addressing serious or life-threatening diseases supported by initial clinical evidence of meeting unmet medical needs.

In February 2023, the Jeffrey Modell Foundation (JMF), a non-profit organization dedicated to primary immunodeficiency, entered into a collaboration with Veritas Intercontinental, a healthcare solutions company based in Spain. The collaboration's primary objective is to advance the field of genome and exome sequencing in the context of immunological disorders. By leveraging global expertise and resources, the partnership seeks to identify gene abnormalities associated with primary immunodeficiency conditions, including conditions such as leukocyte adhesion deficiency. This joint effort aims to significantly improve the accuracy of diagnosis and treatment protocols by enhancing the understanding of genetic factors contributing to these immunological disorders.

Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

North America was the largest region in the leukocyte adhesion deficiency management market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the leukocyte adhesion deficiency management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leukocyte adhesion deficiency management market consists of revenues earned by entities by providing services such as gene therapy, granulocyte transfusions, nutrition, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukocyte adhesion deficiency management market also includes sales of antibiotics such as trimethoprim and sulfamethoxazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary treatments for managing leukocyte adhesion deficiency include hematopoietic stem cell transplantation, recombinant human interferon-gamma treatment, prophylactic immunoglobulin therapy, antimicrobial therapy, prophylactic therapy, fucose supplementation, monoclonal antibodies, and coagulation factors. Hematopoietic stem cell transplantation involves transplanting stem cells from the bone marrow or blood to replace damaged or diseased blood-forming cells. Treatment and diagnostic services, such as blood tests, genetic testing, biopsies, are provided by various end users, including hospitals and specialty clinics.

The leukocyte adhesion deficiency management market research report is one of a series of new reports that provides leukocyte adhesion deficiency management market statistics, including leukocyte adhesion deficiency management industry global market size, regional shares, competitors with a leukocyte adhesion deficiency management market share, detailed leukocyte adhesion deficiency management market segments, market trends and opportunities, and any further data you may need to thrive in the leukocyte adhesion deficiency management industry. This leukocyte adhesion deficiency management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.